Wide Ranks

CMMB

Chemomab Therapeutics Ltd.

1.78

Top Statistics
Market Cap 33 M Forward PE -50.86 Revenue Growth 0.00 %
Current Ratio 3.12 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -28.00 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 12 M Total Cash Per Share 0.0440 Total Debt 360000
Total Debt To Equity 3.60 Current Ratio 3.12 Book Value Per Share 1.20
All Measures
Short Ratio 115.00 % Message Board Id finmb_323539890 Shares Short Prior Month 72487
Return On Equity -0.9380 City Tel Aviv Uuid f2fd6842-2d35-37be-bf48-b334c1a2bb54
Previous Close 1.59 First Trade Date Epoch Utc 1 B Book Value 1.20
Beta 0.3030 Total Debt 360000 Volume 144121
Price To Book 1.49 Last Split Date 1 B Fifty Two Week Low 0.4200
Total Cash Per Share 0.0440 Shares Short Previous Month Date 1 B Target Median Price 9.00
Max Age 86400 Recommendation Mean 1.67 Sand P52 Week Change 0.3133
Target Mean Price 8.00 Net Income To Common -14997000 Short Percent Of Float 0.0087
Implied Shares Outstanding 11 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 123770 Average Volume10days 123770 Total Cash 12 M
Next Fiscal Year End 1 B Held Percent Insiders 0.1129 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 1.59
Target Low Price 4.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.51
Open 1.64 Free Cashflow -11364375 Dividend Yield 0.00 %
Return On Assets -0.4618 Time Zone Short Name EST Trailing Eps -0.9400
Day Low 1.59 Address1 Building 7 Shares Outstanding 18 M
Price Hint 4 Target High Price 11.00 Website https://www.chemomab.com
52 Week Change 2.30 Average Volume 187160 Forward Eps -0.0400
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 310.60 %
Last Split Factor 1:16 Regular Market Day High 1.80 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 3.60 Fifty Two Week High 2.55
Day High 1.80 Shares Short 162900 Regular Market Open 1.64
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0086 Operating Cashflow -16130000 Currency USD
Time Zone Full Name America/New_York Market Cap 33 M Is_nasdaq_100 False
Zip 6158002 Quote Type EQUITY Industry Biotechnology
Long Name Chemomab Therapeutics Ltd. Regular Market Day Low 1.59 Held Percent Institutions 0.2799
Current Price 1.78 Address2 Kiryat Atidim Enterprise To Ebitda -28.00
Financial Currency USD Current Ratio 3.12 Industry Disp Biotechnology
Number Of Analyst Opinions 3 Country Israel Float Shares 169 M
Two Hundred Day Average 1.15 Enterprise Value 447 M Forward PE -50.86
Regular Market Volume 144121 Ebitda -15969000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Chemomab Therapeutics Ltd.

, a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.

Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Chemomab Therapeutics Ltd.

was founded in 2011 and is based in Tel Aviv, Israel.